Európska únia - bulharčina - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - Денга - Ваксини - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 и 4. Използването на dengvaxia трябва да бъде в съответствие с официалните препоръки.

Európska únia - bulharčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - Неоплазми на гърдата - Антинеопластични средства - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Európska únia - bulharčina - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Európska únia - bulharčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - леналидомид - Множествена миелома - Имуносупресори - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) е показан за лечение на възрастни пациенти с по-рано нелекувана множествена миеломой, на които не се разчита за трансплантация. Акорд леналидомид в комбинация с дексаметазоном е показан за лечение на множествена миеломы при възрастни пациенти, които са получили най-малко един курс на терапия. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Európska únia - bulharčina - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - Карцином, сквамозна клетка - Антинеопластични средства - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Bulharsko - bulharčina - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v - Бордетеллы bronchiseptica, жив щам-c2; вируса на кучешки, parainfluenza, жив щам Корнел - лиофилизат и разтворител за капки за нос - ≥ 10 на степен 8 - 10 на степен 9, 7 cfu; ≥ 10 на степен 3 - 10 на степен 5, 8 tcid50 - кучета

Európska únia - bulharčina - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - рекомбинантный вирус везикулярного стоматит (щам Индиана) със заличаването на плик гликопротеин, заменени от Ебола Заир (щам киквите 1995) повърхностен гликопротеин - Хеморагична Треска Ебола - Ваксини - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. Използването на ervebo трябва да бъде в съответствие с официалните препоръки.

Európska únia - bulharčina - EMA (European Medicines Agency)

bayer healthcare ag - прадофлоксацин - Антибактериални средства за системна употреба - Кучета - Куче: инфекции на кожата и меките тъкани, аз. повърхностни и дълбоки пиодермии и раневых инфекции, причинени от грамположительными микроорганизми, обикновено стафилокок ПТ. и streptococcus ПТ. и грам-отрицателни микроорганизми, като например е. коли, синегнойная ПТ. и Протеус ПТ. Инфекции на пикочните пътища, причинени от грам-отрицателни бактерии, като например бактерии от семейство enterobacteriaceae, e. Е. коли, enterobacter ѕрр. , Клебсиелла ПТ. и Протеус ПТ. , Синегнойная ПТ. и грам положителни организми, като правило, staphylococcus ПТ. Инфекция на венците и тъканите на пародонта, причинени от анаеробни организми, например, porphyromonas ПТ. , Превотелл ПТ. ; fusobacterium ѕрр. , Эйкенеллу ПТ. и capnophilic бактерии, като capnocytophaga ПТ. , , cats:, infections of the respiratory tract caused by gram-negative organisms such as pasteurella spp. , Коли и pseudomonas ПТ. и грамположительные микроорганизми, като streptococcus ПТ. и стафилокок ПТ.

Európska únia - bulharčina - EMA (European Medicines Agency)

bavarian nordic a/s - холерный вибрион, щам и ИЗРАВНИТЕЛНИТЕ 103-hgr за да живеят - холера - Ваксини - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. Тази ваксина трябва да се използва в съответствие с официалните препоръки.

Európska únia - bulharčina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.